These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 21710803)

  • 21. Progesterone and preterm delivery--deja vu all over again.
    Greene MF
    N Engl J Med; 2003 Jun; 348(24):2453-5. PubMed ID: 12802032
    [No Abstract]   [Full Text] [Related]  

  • 22. [A case of total regression of endometrial carcinoma metastases in the lung under hormonal therapy (author's transl)].
    Caminati M; Hauser GA
    Ther Umsch; 1979 Jun; 36(6):516-7. PubMed ID: 462406
    [No Abstract]   [Full Text] [Related]  

  • 23. 17alpha-hydroxyprogesterone caproate for the prevention of preterm delivery: A cost-effectiveness analysis.
    Odibo AO; Stamilio DM; Macones GA; Polsky D
    Obstet Gynecol; 2006 Sep; 108(3 Pt 1):492-9. PubMed ID: 16946206
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Medication safety is still an issue in obstetrics 50 years after the Kefauver-Harris amendments: the case of progestogens.
    O'Brien JM
    Ultrasound Obstet Gynecol; 2013 Sep; 42(3):247-53. PubMed ID: 23495199
    [No Abstract]   [Full Text] [Related]  

  • 25. 17 Progesterone for preterm birth prevention: a potential 2 billion dollar opportunity.
    Armstrong J
    Am J Obstet Gynecol; 2007 Mar; 196(3):194-5. PubMed ID: 17346520
    [No Abstract]   [Full Text] [Related]  

  • 26. PPPs succeeding in tackling neglected diseases.
    Frantz S
    Nat Rev Drug Discov; 2005 Oct; 4(10):796-7. PubMed ID: 16237841
    [No Abstract]   [Full Text] [Related]  

  • 27. Bush veto fuels orphan drug act uncertainties.
    Gershon D
    Nature; 1990 Nov; 348(6298):185. PubMed ID: 2234086
    [No Abstract]   [Full Text] [Related]  

  • 28. [Oxyprogesterone capronate in the treatment of menstrual epilepsy].
    Badalian LO; Temin PA; Mukhin KIu
    Ross Med Zh; 1992; (3):41-4. PubMed ID: 1643360
    [No Abstract]   [Full Text] [Related]  

  • 29. Orphan products development and some methods for maximizing the usefulness of research on rare diseases.
    Finkel MJ
    Prog Clin Biol Res; 1985; 197():11-8. PubMed ID: 4070285
    [No Abstract]   [Full Text] [Related]  

  • 30. [Problems in the treatment of excessive growth in children using sex hormones].
    Straková M; Krejcová M; Kadlecová I; Nováková J
    Cesk Pediatr; 1982 Oct; 37(10):594-6. PubMed ID: 7172309
    [No Abstract]   [Full Text] [Related]  

  • 31. Review of regulatory recommendations for orphan drug submissions in the Netherlands and Scotland: focus on the underlying pharmacoeconomic evaluations.
    Vegter S; Rozenbaum MH; Postema R; Tolley K; Postma MJ
    Clin Ther; 2010 Aug; 32(9):1651-61. PubMed ID: 20974323
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rarefied drug pricing.
    Nat Biotechnol; 2014 May; 32(5):398. PubMed ID: 24811493
    [No Abstract]   [Full Text] [Related]  

  • 33. Mission possible.
    Hopkins AL; Witty MJ; Nwaka S
    Nature; 2007 Sep; 449(7159):166-9. PubMed ID: 17851512
    [No Abstract]   [Full Text] [Related]  

  • 34. Lucrative niches: how drugs for rare diseases became lifeline for companies.
    Anand G
    Wall St J (East Ed); 2005 Nov; ():A1, A18. PubMed ID: 16502531
    [No Abstract]   [Full Text] [Related]  

  • 35. Drugs bill to rein in profits.
    Gershon D
    Nature; 1994 Mar; 368(6470):381. PubMed ID: 8133874
    [No Abstract]   [Full Text] [Related]  

  • 36. Prescription for the Orphan Drug Act: the impact of the FDA's 1992 regulations and the latest congressional proposals for reform.
    Clissold DB
    Food Drug Law J; 1995; 50(1):125-47. PubMed ID: 10342989
    [No Abstract]   [Full Text] [Related]  

  • 37. CMS move threatens to put orphan drugs out in cold.
    Carroll J
    Manag Care; 2003 Jul; 12(7):10-1. PubMed ID: 12891947
    [No Abstract]   [Full Text] [Related]  

  • 38. Can we help one billion sick people?
    Maliski E; Gund P; Brown F
    Curr Opin Drug Discov Devel; 2008 May; 11(3):301-2. PubMed ID: 18428082
    [No Abstract]   [Full Text] [Related]  

  • 39. Pharmaceuticals, patents, publicity...and philanthropy?
    Lancet; 2009 Feb; 373(9665):693. PubMed ID: 19249610
    [No Abstract]   [Full Text] [Related]  

  • 40. Developing drugs for developing countries.
    Ridley DB; Grabowski HG; Moe JL
    Health Aff (Millwood); 2006; 25(2):313-24. PubMed ID: 16522573
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.